Abstract 5117
Background
Monocyte-lymphocyte, neutrophil-lymphocyte and platelet-lymphocyte ratio are considered prognostic tools of overall survival (OS) in several hematologic and solid tumors. All these elements have been implicated as biomarkers of tumor microenvironment and immune homeostasis. Mantle cell lymphoma (MCL) is a relatively uncommon subtype of lymphoid malignancy (5%–7% of malignant lymphoma) but could be very aggressive. Mantle Cell Lymphoma International Prognostic Index (MIPI) is the only validated prognostic tool for these patients. The aim of this study assessed the prognostic significance of monocyte-lymphocyte, neutrophil-lymphocyte and platelet-lymphocyte ratio as prognostic biomarkers for MCL.
Methods
An observational retrospective study was conducted and included a total all the patients diagnosed with MCL between 2008-2018 in our hematologic center. The ratios were calculated, and statistical analysis were assessed using Kaplan-Meier method, log-rank test and Cox regression. All the analyses were performed using SPSS.
Results
A total of 52 patients were included, 75% were male, with the median age at diagnosis being 67 years-old (max 94, min 36 years old). 77% of the patients had an ECOG PS 0-1, 67% had a high risk MIPI and 73% were a stage IV disease at diagnosis. Kaplan-Meier analysis showed that MIPI score significantly predicts the OS of the patients, with the higher scores being associated with inferior OS (p = 0,02). The same did not happen with the monocyte-lymphocyte ratio (p = 0,5), neutrophil-lymphocyte ratio (p = 0,4) and platelet-lymphocyte ratio (p = 0,3). The same results were showed in cox regression, MIPI score remained the only score associated with OS (HR, 0,35; 95% CI 0,132-0,962).
Conclusions
In conclusion, this study fails to identify monocyte-lymphocyte, neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic tools and support MIPI as predictor of the survival outcome in MCL patients and its ability to identify high-risk patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1269 - One-year follow-up results of eribulin for soft-tissue sarcoma including rare subtypes in a real-world observational study in Japan
Presenter: Shunji Takahashi
Session: Poster Display session 1
Resources:
Abstract
2868 - Prevalence of chemotherapy use and its impact on overall survival in patients with bone- and soft tissue sarcomas -A population-based analysis of 3746 patients
Presenter: Herbert Loong
Session: Poster Display session 1
Resources:
Abstract
3042 - Clinical course and therapeutic management of classical and endemic Kaposi’s Sarcoma (C/E KS)
Presenter: Lina Benajiba
Session: Poster Display session 1
Resources:
Abstract
3141 - The final outcomes of study on combined therapy of adult patients with localized synovial sarcoma
Presenter: Katarzyna Kozak
Session: Poster Display session 1
Resources:
Abstract
5449 - Real-world Outcomes of Patients with Locally Advanced or Metastatic Epithelioid Sarcoma
Presenter: Mrinal Gounder
Session: Poster Display session 1
Resources:
Abstract
4465 - SAKK 57/16 Nab-Paclitaxel And Gemcitabine in soft tissue sarcoma (NAPAGE): results from the phase I part of a phase I/II trial
Presenter: Antonia Digklia
Session: Poster Display session 1
Resources:
Abstract
5013 - Outcome of 98 patients with epithelioid sarcoma treated in curative intent: a retrospective study from the French Sarcoma Group (GSF-GETO)
Presenter: Maud Pedrono
Session: Poster Display session 1
Resources:
Abstract
5614 - Comparison of filgrastim and pegfilgrastim prophylaxis in sarcoma patients receiving highly myelosuppressive chemotherapy.
Presenter: Paolo Tarantino
Session: Poster Display session 1
Resources:
Abstract
1033 - Access to clinical trials for soft tissue sarcoma patients in Western and Eastern Europe
Presenter: Vasilii Ostafiichuk
Session: Poster Display session 1
Resources:
Abstract
4094 - Treatment outcomes for adult patients with localized osteosarcoma treated with chemotherapy without methotrexate
Presenter: Marília Silva
Session: Poster Display session 1
Resources:
Abstract